Objectives of this Study:-
# To define, measure, and describe the global human liver model market by type and region
# To provide detailed information about the major factors influencing market growth (drivers, restraints, challenges, and opportunities)
# To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
# To forecast the size of market segments in North America, Europe, Asia Pacific, and RoW
Global Market Dynamics:
Major Industry Growth Drivers:
# Growing Focus on Developing Alternatives for Animal Testing Models
# Significant Increase in Research Funding and Venture Capital Investments for the Development of Liver Organoids
# Growing Initiatives to Increase Awareness about Liver Organoids
# Increasing Research Activities on Liver Organoids
# Increasing Prevalence of Non-Alcoholic Fatty Liver Disease
# Growing Need for the Early Detection of Drug Toxicity to Minimize Financial Losses Due to Late-Stage Drug Failure
Looking Out for More Details | Download the PDF Brochure
Major Growth Restraints:
# Issues Related to the Incorporation of Organoids into Existing Workflows
Opportunities:
# Increasing Focus on Drug Discovery Activities
# Rising Demand for Liver Transplantation
# Growing Healthcare Market in the Asia Pacific and Latin America
Industry’s Revenue Growth Expectations:
The global human liver models market is expected to reach USD 2.56 Billion by 2022 from USD 1.35 Billion in 2017, at a CAGR of 13.6% during the forecast period (2017-2022).
Geographical Growth Scenario:
Geographic segments in this report include North America, Europe, Asia Pacific, and the RoW. Of these, the North American segment accounted for the largest share of the market in 2017. The human liver market for North America is driven by the presence of a well-established life sciences industry, growing awareness about the organoids technology, increasing government funding, growing incidence of NAFLD, and unavailability of livers for transplantation, increasing investments on research, rising focus on tissue culture-based clinical diagnostics, and the availability of skilled professionals.
Read More: https://www.marketsandmarkets.com/PressReleases/human-liver-model.asp
Leading Market Players:
The major players in the global human liver model market are Emulate (US), Ascendance Bio (US), HìREL (US), CN Bio (UK), Organovo (US), and Cyfuse Biomedical (Japan).
The global liver 3D bioprinting market was dominated by Organovo Holdings, Inc. (US). With its broad product portfolio, Organovo Holdings, Inc. held the leadership position in the global 3D bioprinting market for liver in 2016. Its large market share is attributed to its robust 3D bioprinting portfolio. In addition, the company is focusing on various strategies to expand its product offerings and increase its visibility in the 3D bioprinting market.
In line with this, the company has collaborated with various research organizations and pharmaceutical companies for developing novel products. For instance, in June 2016, Organovo collaborated with the University of California, San Francisco (UCSF) for developing 3D bioprinted tissues, to be used for research on skeletal disease. Similarly, in December 2014, Organovo collaborated with the Yale School of Medicine, Department of Surgery (US) with the aim to develop 3D organ tissues for surgical transplantation research.
Target Audience:
# Pharmaceutical and biotechnology companies
# Chemical companies
# Cosmetic product manufacturers, suppliers, and distributors
# Healthcare providers and diagnostic laboratories
# Manufacturers of 3D Cell Culture products
# Food & beverage manufacturers
# Contract research organizations (CROs)
# Research institutes/universities# Research and consulting firms
# Venture capitalists
